ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
The impact of uterine position during brachytherapy on treatment outcomes and toxicity in patients with cervical cancer.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of uterine position during brachytherapy on dosimetric parameters, oncologic outcomes, and toxicity in cervical cancer patients treated with external beam radiotherapy (EBRT) followed by high-dose-rate intracavitary brachytherapy (HDR-ICBT).
methodsA retrospective analysis was conducted on 278 non-metastatic cervical cancer patients treated between 2012 and 2022. All received 45-50.4 Gy EBRT followed by 28 Gy HDR-ICBT in four fractions. Uterine position was documented for each ICBT fraction, and patients with inter-fraction variations were excluded.
resultsIn total, 251 patients met the inclusion criteria: 222 (88%) had an anteverted and 29 (12%) had a retroverted uterus. Median follow-up was 44 months (range: 1-134 months). The 2- and 5‑year overall survival rate was 82% and 71% for an anteverted vs. 77% and 77% for a retroverted uterus (p = 0.8). Local recurrence developed in 21 (10%) and three (11%) patients, respectively (p = 0.89). Median doses to the high- and intermediate-risk clinical target volumes (CTV) were higher with an anteverted uterus (91.3 vs. 89.8 Gy, p = 0.001; and 67.4 vs. 65.9 Gy, p = 0.044). A retroverted uterus was associated with higher rectum (76.3 vs. 79.7 Gy, p = 0.001) and bowel doses (66.4 vs. 73.7 Gy, p = 0.023), yet lower sigmoid doses (63.4 vs. 59.9 Gy, p = 0.005). Severe toxicity rates were similar, although late grade 1-2 gastrointestinal toxicity was more frequent in the retroverted group (4% vs. 17%, p = 0.019).
conclusionA retroverted uterine position during ICBT was associated with lower CTV doses and higher rectum and bowel doses while oncologic outcomes and severe toxicity remained comparable.
Indexed as
Identifiers
42547651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.